BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, LLC is pleased to announce that its generic Felbamate tablets are now available in 400 mg and 600 mg strengths. Amneal’s latest First-to-Market product is an AB-rated, therapeutically equivalent alternative to the antiepileptic drug Felbatol® (a registered trademark of Meda Pharmaceuticals Inc.). Annual U.S. sales of Felbatol® are $43.7 million according to January 2011 IMS Health market data. Amneal received U.S. FDA approval to manufacture Felbamate tablets on September 13, 2011.
